Enhancing lentiviral vector stability and recovery: optimizing buffer formulation

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Lentiviral vectors (LVV) are critical tools in both in vivo gene therapy and ex vivo cell therapy manufacturing and have been extensively used for investigational and commercial purposes. Despite existing buffer formulations, there are significant opportunities to develop more robust LVV formulation buffer systems that improve stability and consequently increase recovery of infectious virus.

In this webinar, we will delve into a detailed case study showcasing our work conducting design of experiments (DoE) to optimize LVV stability. We will examine how different storage environments and formulations influence both short-term and long-term stability for GMP-compliant LVV production.

• Learn how DoE can be utilized to optimize buffer formulations that enhance LVV stability
• Understand key factors affecting LVV stability, including buffer composition, additives, and virus concentration
• Explore testing conditions for analysing short-term and long-term LVV stability

Jessica Tate

VP of Viral Vector Platform Technology at CCRM & OmniaBio

For over 20 years, Dr. Jessica Tate has been at the forefront of viral vector research, leading transformative advancements within the gene therapy industry. With a Ph.D. in molecular genetics from the University at Buffalo, she has applied her extensive expertise to advance more than 70 viral vector products, four of which have progressed to pivotal or commercial stages. As a seasoned leader, Jessica has excelled in key areas, such as process development, technology transfer, and process characterization, while also building and scaling new teams and facilities. Her contributions to the field are further solidified by several publications and U.S. patents, showcasing her role as a true pioneer in viral vector technologies. Currently, as the Vice President of Viral Vector Platform Technology at CCRM, Jessica directs strategic initiatives and oversees the development of robust and scalable viral vector processes and analytics. The developed technologies are offered through OmniaBio to its therapeutic clients, driving success and maturity in the cell and gene therapy space.

Watch now

SPEAKERS

Jessica Tate

VP of Viral Vector Platform Technology at CCRM & OmniaBio

You might also like

Optimizing lentiviral purification: enhancing chromatography with monoliths

Luka Bevc

4 December

Watch

Scalable solutions for optimizing lentiviral vector production

Vera Ortseifen, Kathrin Teschner

11 December

Watch

Innovative approaches to lentiviral vector purification: achieving high yields and purity with a chromatography-free process

Nikki Votaw

20 August

Watch

Enhancing CAR-T cell generation: optimizing non-viral engineering of resting T cells for improved cancer immunotherapy

Akshaya Chandrasekaran

2 May

Watch